Table 3 Changes in lung function, inflammatory markers, and biochemical analyses
From: Exposure to volatile organic compounds and airway inflammation
Before move (n = 34) | After move (n = 34) | p-value | |
|---|---|---|---|
Lung function testsa | |||
FEV1, L | 2.51 (0.69–4.05) | 2.44 (1.39–3.96) | 0.688 |
FEV1, % | 90 (30–119) | 93 (64–118) | 0.410 |
FVC, L | 3.14 (1.01–5.06) | 3.03 (1.82–5.19) | 0.688 |
FVC, % | 90 (33–118) | 91 (70–111) | 0.448 |
FEV1/FVC | 80 (65–89) | 80 (67–90) | 0.734 |
FEV25–75, L/s | 2.71 (0.39–6.08) | 2.57 (0.72–4.95) | 0.899 |
FEV25–75, % | 90 (19–168) | 94 (33–190) | 0.959 |
FeNO (ppm) | 21 (11–43) | 19 (7–44) | 0.040 |
uLTE4 (pg/ml) | 252.4 (36.8–5889.5) | 460.6 (15.0–5570.9) | 0.005 |
FeNO / uLTE4 | 11.1 (1.2–145.4) | 20.7 (0.7–206.3) | 0.004 |
Oxidative stress biomarkers | |||
MDA (μmol/g Cr.) | 1.3 (0.4–8.8) | 1.4 (0.4–3.3) | 0.578 |
8-OHdG (ng/mg Cr.) | 3.4 (0.6–8.2) | 3.0 (0.3–8.3) | 0.351 |
VOC metabolites | |||
t,t-MA (μg/g Cr) | 85.8 (30.2–623.8) | 68.0 (9.5–347.0) | 0.012 |
HA (mg/g Cr) | 204.4 (8.6–1984.9) | 272.9 (18.0–1978.1) | 0.714 |
MA (μg/g Cr) | 183.5 (68.7–440.6) | 215.1 (71.3–2481.6) | 0.118 |
PGA (μg/g Cr) | 47.4 (4.9–431.6) | 63.4 (3.9–431.8) | 0.966 |
o-MHA (μg/g Cr) | 60.7 (12.2–307.0) | 99.7 (30.3–299.6) | 0.000 |
m-MHA (μg/g Cr) | 101.7 (25.9–912.2) | 164.6 (80.4–453.6) | 0.002 |
p-MHA (μg/g Cr) | 52.4 (17.5–401.3) | 88.6 (30.2–630.9) | 0.000 |